Home > Insider Trading > Filing (0001493152-23-017792)

Filing Details

Accession Number:: 0001493152-23-017792
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-05-16 16:16:10
Reporting Period:: 2023-05-12

Accepted Time:: 2023-05-16 16:16:10
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1433607	Inspiremd Inc.	NSPR	Surgical & Medical Instruments & Apparatus (3841)	262123838

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1528577	Paul Stuka	C/O Inspiremd, Inc. 4 Menorat Hamaor St. Tel Aviv L3 6744832		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-05-12	175,000	$1.63	248,534	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series H Warrants to purchase Common Stock	Acquisiton	2023-05-12	87,500	$1.63	87,500	$1.38
Common Stock	Series I Warrants to purchase Common Stock	Acquisiton	2023-05-12	87,500	$1.63	87,500	$1.38
Common Stock	Series J Warrants to purchase Common Stock	Acquisiton	2023-05-12	87,500	$1.63	87,500	$1.38
Common Stock	Series K Warrants to purchase Common Stock	Acquisiton	2023-05-12	87,500	$1.63	87,500	$1.38

Remaning Holdings	Exercise Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
87,500	2023-05-15	No	4	P	Indirect
87,500	2023-05-15	No	4	P	Indirect
87,500	2023-05-15	No	4	P	Indirect
87,500	2023-05-15	No	4	P	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	42,320	Direct

Footnotes

The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").
The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.
These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.
The aggregate number of warrants reported in this row consists of 87,500 Series H Warrants that were acquired in the Private Placement.
The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial.
The aggregate number of warrants reported in this row consists of 87,500 Series I Warrants that were acquired in the Private Placement.
The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm).
The aggregate number of warrants reported in this row consists of 87,500 Series J Warrants that were acquired in the Private Placement.
The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm.
The aggregate number of warrants reported in this row consists of 87,500 Series K Warrants that were acquired in the Private Placement.
The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin.